Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

NCT05733715 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Pembrolizumab infusion
DRUG: Lenvatinib tablet

Sponsor

Abramson Cancer Center at Penn Medicine

Collaborators

[object Object]